Share this article

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.

The transaction enables the two companies to strengthen their urinary disorders product portfolio.

Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares.

Subscribed to by Roivant Sciences, the placement will enable Arbutus to accelerate the development of its HBV drug pipeline.

Research company Gesynta Pharma has acquired pharmaceuticals developer Orexo’s assets relating to the OX-MPI programme.

“Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares.”

The deal will help the company to advance its OX-MPI project into the clinical stage.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Both companies involved in the deal are based in Sweden.

KSQ Therapeutics has secured $76m in a venture financing round led by Flagship Pioneering.

The US-based biotechnology company plans to use the funds in order to advance its research and development activities.

Bermuda-based biopharmaceutical company SELLAS Life Sciences Group (SELLAS) has signed a clinical trial collaboration agreement with US-based pharmaceutical company Merck & Co’s subsidiary.

The two companies will carry out a combination clinical trial with galinpepimut-S and KEYTRUDA, under the agreement.

The trial will target multiple cancer types, including haematologic malignancies and solid tumours.